CrystecPharma CEO Paul Thorning will attend the Partnership Opportunities in Drug Delivery (PODD) conference in Boston on 29–30 October 2026.
Now in its 16th year, PODD brings together leaders from the pharmaceutical, biotechnology and drug delivery sectors to explore emerging technologies, discuss development challenges and build new partnerships. The conference covers scientific and business developments across small molecules, biologics, combination products, connected devices, and cell and gene delivery, with dedicated networking and partnering opportunities throughout the event.
Paul looks forward to connecting with fellow innovators and exploring how Crystec’s proprietary modified Supercritical Anti-Solvent (mSAS®) particle engineering technology can help address formulation and delivery challenges.
Through precise control of particle size, morphology and solid-state properties, mSAS® supports the development of engineered particles for small molecules and biologics. Applications include improving dissolution, supporting biomolecule stability and developing powders for inhaled delivery or reconstitution, creating opportunities to enhance product performance and explore alternative routes of administration.
If you are attending PODD 2026, please say hello or get in touch through the PODD partnering app to arrange a meeting with Paul.